ArticleESMO open2023

Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.

K Tamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.